The CFTR corrector lumacaftor and the potentiator ivacaftor were proven in combination (LUM/IVA) as first causative treatment designed to rescue CFTR protein function in patients with CF homozygous for the F508del variant (F/F). This evidence concerns the gene CFTR and cystic fibrosis.